Industry News (Reacquisition)

Positive Results Demonstrated in Phase III Studies Interim Analysis

Published in Cancer Weekly, July 28th, 1997

The Liposome Company, Inc., Princeton, New Jersey, announced that it has reacquired all development, manufacturing, and marketing rights to TLC D-99, liposomal doxorubicin, from its development partner, Pfizer Inc.

TLC D-99 currently is being studied in two Phase III clinical trials in metastatic breast cancer in the U.S. and in a third study in Europe. In the U.S., a single agent study is designed to compare TLC D-99 to conventional doxorubicin. The combination study compares the two drugs when each is administered with cyclophosphamide.

The primary end point of the studies is to demonstrate that TLC D-99 is significantly safer with regard to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-07-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry